Thiadiazolidinone-8 (TDZD-8) is an effective thiadiazolidinone derivate that is able to suppress the expression of inflammatory cytokines; it also presents tissue protective actions by glycogen synthase kinase (GSK)-3β inhibition, promoting thus an anti-inflammatory effect. Since inflammatory bowel disease is a chronic disease with reduced quality of life, where currently available therapies are only able to induce or maintain the patient in remission, it is crucial to investigate new pharmacological approaches. The main objective of this study was to evaluate the effect of TDZD-8 in 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis. Male CD-1 mice with TNBS-induced colitis were treated with a daily dose of TDZD-8 5 mg/kg/day IP during 4 days. The anti-inflammatory properties of TDZD-8 in the TNBS-induced colitis were confirmed by suppression of pro-inflammatory mediators, such as tumor necrosis factor (TNF)-α, interleukin (IL)-1β and myeloperoxidase, as well as by the significant increase of the anti-inflammatory cytokine, IL-10. These treated mice also presented a reduction in fecal hemoglobin and alkaline phosphatase, suggesting a beneficial effect of TDZD-8. Furthermore, renal and hepatic biomarkers remained stabilized after treatment. In conclusion, TDZD-8 reduces the inflammatory response associated with TNBS-induced colitis in mice, and modulation of GSK-3β seems to be an interesting pharmacological target in colitis.

1.
Pithadia A, Jain S: Treatment of inflammatory bowel disease (IBD). Pharmacol Rep 2011;63:629-642.
2.
Hanauer S: Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis 2006;12:3-9.
3.
Spiegel B: The burden of IBS: looking at metrics. Curr Gastroenterol Rep 2009;11:265-269.
4.
Engel M, Neurath M: New pathophysiological insights and modern treatment of IBD. J Gastroenterol 2010;45:571-583.
5.
Martinez A, Alonso M, Castro A, Pérez C, Moreno F: First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J Med Chem 2002;45:1292-1299.
6.
Martinez A, Castro A, Dorronsoro I, Alonso M: Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Med Res Rev 2002;22:373-384.
7.
Dugo L, Collin M, Thiemermann C: Glycogen synthase kinase 3beta as a target for the therapy of shock and inflammation. Shock 2007;2:113-123.
8.
Meijer L, Flajolet M, Greengard P: Pharmacological inhibitors of glycogen synthase kinase 3. Trends Pharmacol Sci 2004;25:471-480.
9.
Buss H, Dörrie A, Schmitz ML, Frank R, Livingstone M, Resch K, Kracht M: Phosphorylation of serine 468 by GSK-3beta negatively regulates basal p65 NF-kappaB activity. J Biol Chem 2004;279:49571-49574.
10.
Luna-Medina R, Cortes-Canteli M, Alonso M, Santos A, Martínez A, Perez-Castillo A: Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivatives through peroxisome proliferator activated receptor gamma activation. J Biol Chem 2005;280:21453-21462.
11.
Whittle B, Varga C, Pósa A, Molnár A, Collin M, Thiemermann C: Reduction of experimental colitis in the rat by inhibitors of glycogen synthase kinase-3beta. Br J Pharmacol 2006;147:575-582.
12.
Low D, Nguyen DD, Mizoguchi E: Animal models of ulcerative colitis and their application in drug research. Drug Des Devel Ther 2013;7:1341-1357.
13.
Mateus V, Rocha J, Alves P, Mota-Filipe H, Sepodes B, Pinto RM: Anti-inflammatory effect of erythropoietin in the TNBS-induced colitis. Basic Clin Pharmacol Toxicol 2017;120:138-145.
14.
Corazza N, Eichenberger S, Eugster HP, Mueller C: Nonlymphocyte-derived tumor necrosis factor is required for induction of colitis in recombination activating gene (rag)2(-/-) mice upon transfer of Cd4+Cd45rbhi T cells. J Exp Med 1999;190:1479-1492.
15.
Seamons A, Treuting PM, Brabb T, Maggio-Price L: Characterization of dextran sodium sulfate-induced inflammation and colonic tumorigenesis in smad3(-/-) mice with dysregulated TGFβ. PLoS One 2013;8:e79182.
16.
Cohen P, Goedert M: GSK3 inhibitors: development and therapeutic potential. Nat Rev Drug Discov 2004;3:479-487.
17.
Beurel E, Michalek SM, Jope RS: Innate and adaptive immune responses regulated by glycogen synthase kinase-3 (GSK3). Trends Immunol 2009;1:24-31.
18.
Dugo L, Collin M, Allen DA, Patel NS, Bauer I, Mervaala EM, Louhelainen M, Foster SJ, Yaqoob MM, Thiemermann C: GSK-3beta inhibitors attenuate the organ injury/dysfunction caused by endotoxemia in the rat. Crit Care Med 2005;33:1903-1912.
19.
Kornbluth A, Sachar DB: Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010;105:501-523.
20.
Hirata I, Hoshimoto M, Saito O, Hirata I, Hoshimoto M, Saito O, Kayazawa M, Nishikawa T, Murano M, Toshina K, Wang FY, Matsuse R: Usefulness of fecal lactoferrin and hemoglobin in diagnosis of colorectal diseases. World J Gastroenterol 2007;13:1569-1574.
21.
Jagtap AG, Niphadkar PV, Phadke AS: Protective effect of aqueous extract of Bombax malabaricum DC on experimental models of inflammatory bowel disease in rats and mice. Indian J Exp Biol 2011;49:343-351.
22.
Kumar VS, Rajmane AR, Adil M, Kandhare AD, Ghosh P, Bodhankar SL: Naringin ameliorates acetic acid induced colitis through modulation of endogenous oxido-nitrosative balance and DNA damage in rats. J Biomed Res 2014;28:132-145.
23.
Malo MS, Alam SN, Mostafa G, Zeller SJ, Johnson PV, Mohammad N, Chen KT, Moss AK, Ramasamy S, Faruqui A, Hodin S, Malo PS, Ebrahimi F, Biswas B, Narisawa S, Millán JL, Warren HS, Kaplan JB, Kitts CL, Hohmann EL, Hodin RA: Intestinal alkaline phosphatase preserves the normal homeostasis of gut microbiota. Gut 2010;59:1476-1484.
24.
Nagalingam NA, Kao JY, Young VB: Microbial ecology of the murine gut associated with the development of dextran sodium sulfate-induced colitis. Inflamm Bowel Dis 2011;17:917-926.
25.
Ukil A, Maity S, Karmarkar S, Datta N, Vedasiromoni J, Das PK: Curcumin, the major component of food flavour turmeric, reduces mucosal injury in trinitrobenzene sulphonic acid-induced colitis. Br J Pharmacol 2003;139:209-218.
26.
Szczepanik M, Góralska M, Marcińska K, Zemelka-Wiącek M, Strzępa A, Dorożyńska II, Szczepanik M: Epicutaneous immunization with protein antigen TNP-Ig alleviates TNBS-induced colitis in mice. Pharmacol Rep 2012;64:1497-1504.
27.
Carty E, De Brabander M, Feakins RM, Rampton DS: Measurement of in vivo rectal mucosal cytokine and eicosanoid production in ulcerative colitis using filter paper. Gut 2000;46:487-492.
28.
Hofmann C, Dunger N, Schölmerich J, Falk W, Obermeier F: Glycogen synthase kinase 3-β: a master regulator of toll like receptor-mediated chronic intestinal inflammation. Inflamm Bowel Dis 2010;16:1850-1858.
29.
Coquerelle C, Oldenhove G, Acolty V, Denoeud J, Vansanten G, Verdebout JM, Mellor A, Bluestone JA, Moser M: Anti-CTLA-4 treatment induces IL-10-producing ICOS+ regulatory T cells displaying IDO-dependent anti-inflammatory properties in a mouse model of colitis. Gut 2009;58:1363-1373.
30.
Yang X, Meng S, Jiang H, Chen T, Wu W: Exosomes derived from interleukin-10-treated dendritic cells can inhibit trinitrobenzene sulfonic acid-induced rat colitis. Scand J Gastroenterol 2010;45:1168-1177.
31.
Puangpraphant S, Dia VP, Mejia EG, Garcia G, Berhow MA, Wallig MA: Yerba mate tea and mate saponins prevented azoxymethane-induced inflammation of rat colon through suppression of NF-κB p65ser(311) signaling via IκB-α and GSK-3β reduced phosphorylation. Biofactors 2013;39:430-440.
32.
Mateus V, Faísca P, Mota-Filipe H, Sepodes B, Pinto R: Development of TNBS-induced colitis: animal model to test new pharmacological approaches. Acta Farm Port 2013;2:89-95.
33.
Larsen S, Bendtzen K, Nielsen OH: Extraintestinal manifestations of inflammatory bowel disease: epidemiology, diagnosis, and management. Ann Med 2010;42:97-114.
34.
Oikonomou K, Kapsoritakis A, Eleftheriadis T, Stefanidis I, Potamianos S: Renal manifestations and complications of inflammatory bowel disease. Inflamm Bowel Dis 2011;17:1034-1045.
35.
Rojas-Feria M, Castro M, Suárez E, Ampuero J, Romero-Gómez M: Hepatobiliary manifestations in inflammatory bowel disease: the gut, the drugs and the liver. World J Gastroenterol 2013;19:7327-7340.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.